Compare TransMedics Group Inc (TMDX) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.77 (market cap $17.53B). The key difference: iShares Broad USD Investment Grade Corporate Bond is far larger — about 6.4× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| TMDX | USIG | |
|---|---|---|
Market Cap | $2.74B | $17.53B |
Volume | 949,331 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $150.42 | $52.69 |
52-Week Low | $61.99 | $48.54 |
Typical Hold Time | 24 Days | 44 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
USIG trades at $48.79 with a slight 0.23% daily gain. Technical indicators show a bearish bias with moving averages signaling caution, though oscillators are neutral. The ETF maintains consistent dividend distributions, with recent payments of $0.20-$0.21 per share. Institutional interest remains strong with Blue Edge Capital and Bank of New York Mellon increasing positions in 2026.
The outlook remains cautious given the bearish technical signals and lack of fundamental financial data. Investment opportunities exist through dividend income and institutional backing, but risks include market volatility and the absence of key valuation metrics for proper assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
